Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
about
The role of preoperative systemic treatment in patients with breast cancerNeoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the LiteratureThe role of taxanes in triple-negative breast cancer: literature reviewChemotherapy-induced peripheral neurotoxicity: a critical analysisPhase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancerProspective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.Five-year survival of metastatic pancreatic carcinoma: a study of courage and hopeThe prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative OncoChanges in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancerModel-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.Profound and persistent painful paclitaxel peripheral neuropathy in a premenopausal patient.Novel formulations of taxanes: a review. Old wine in a new bottle?Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0Management options in triple-negative breast cancerCurrent operative management of breast cancer: an age of smaller resections and bigger cures.Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer.Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis.The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases.Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.Non-Surgical Breast-Conserving Treatment (KORTUC-BCT) Using a New Radiosensitization Method (KORTUC II) for Patients with Stage I or II Breast CancerEfficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer.Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients.Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice.USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancerPhase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
P2860
Q26746034-06787510-D423-4920-8F27-96D3FC3EF1DEQ26751249-9327BFF9-C78A-43F4-894D-D569F2A65506Q26798356-D0CF32EC-464E-429D-95E8-B923FEC871BBQ27010318-650E1B9A-A317-45E5-98CF-818F1D22C681Q28240692-761C3D6A-A6D6-4A9E-B30D-544D41501AF2Q30433483-B70C8DD7-2DE9-404C-B3BA-C17831C9D933Q33382682-3595C77B-4565-47A4-A921-88C7C0747C6BQ33387547-17DBF556-C579-4F6A-828A-4903D17987E1Q33388534-55CB125E-D1E0-4F3E-8960-AB4582159C27Q33402700-6225ADBE-6F9B-4CE3-A4B0-A5F8F7B8B9D8Q33430463-DA3A1CEE-D271-4B23-BD62-656EED717B9BQ33516882-7EE3753B-7934-406F-9DC1-EF3362CAB116Q33591948-EFE4F157-7CDD-4C78-B6A4-1EA8E98BDEC9Q33739381-3650B780-8FAC-4525-9231-44B293644E6BQ33739585-E3F78E9C-2048-49C1-93D1-EBE518001D9EQ33749066-81BE6BBC-0975-4DA9-BCF5-4258FB5E6F23Q33785011-D4BE6825-36C9-48EB-961A-52988CEC3EB9Q33904763-E4479FD6-0ADB-457A-8B35-7252D0BC8F4EQ34042709-87793776-64D4-4F62-9B6F-96E5936C320EQ34059719-B9AED565-25A0-4CEE-BC54-41950B21D089Q34275072-F6709121-53C3-4F9C-AAEE-BA1A94FA3E3DQ34303792-E7718664-AC4E-456A-A335-0AEEE6C2E7D9Q34563540-017E754F-F92B-43E0-9C92-B9A4E3B3D289Q34743442-EF5E72AC-B213-45DE-BAAD-CEA5C75B0BB2Q35155460-3B9B35E5-94CC-4D7E-B7DB-22A9A5F93A79Q35684553-A5BBE235-7796-4055-A9B6-DDD31E3495D9Q35789457-9BB104D1-3A6B-450B-9124-B17C4EBCBA24Q35872171-BA0F1CA1-45DA-4F66-9856-A0AA2A03FC25Q36133814-B2DEEA65-F3A1-4A0B-9D2F-5F25F04D325EQ36245392-5ECC3D40-49C1-492C-B11C-D878BDC7DDCAQ36309028-4E27283B-F497-4D67-A6FB-721B362F27DCQ36355682-D587BC24-355F-43D4-BFB8-B03B36C9832AQ36359684-35DC0CDA-6DFB-465A-83AB-C79C22C6FA99Q36407473-E8692E9A-9FA5-41C9-A026-2F399765D56EQ36416134-CB2651BA-2A86-4CD8-B08D-FE2619F2332DQ36423995-D7CABBF5-D5D2-4590-B18B-D1940DC42528Q36451584-E0B894F0-4BCB-431C-B2F1-4C8C091FF589Q36546612-643E3CD1-1F00-4428-9600-9407E3EF7A0DQ36599308-E6BC8FF1-4BED-4023-9B1D-C2DAB79D927CQ36611760-AA08D554-3DCC-4B34-AAC1-B13082E17F05
P2860
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@en
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@nl
type
label
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@en
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@nl
prefLabel
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@en
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@nl
P2093
P356
P1476
Weekly paclitaxel improves pat ...... paclitaxel once every 3 weeks.
@en
P2093
Aman U Buzdar
Aysegul A Sahin
Cynthia Carter
Daniel J Booser
Debra Frye
Edgardo Rivera
Eric A Strom
Gabriel N Hortobagyi
Kelly K Hunt
Lajos Pusztai
P304
P356
10.1200/JCO.2005.06.232
P407
P577
2005-08-08T00:00:00Z